| Product Code: ETC10756491 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Germany PD-1 Non-Small Cell Lung Cancer Market Overview |
3.1 Germany Country Macro Economic Indicators |
3.2 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, 2021 & 2031F |
3.3 Germany PD-1 Non-Small Cell Lung Cancer Market - Industry Life Cycle |
3.4 Germany PD-1 Non-Small Cell Lung Cancer Market - Porter's Five Forces |
3.5 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Therapy Type, 2021 & 2031F |
3.7 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Treatment Stage, 2021 & 2031F |
3.8 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Mode of Action, 2021 & 2031F |
3.9 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Germany PD-1 Non-Small Cell Lung Cancer Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of non-small cell lung cancer in Germany |
4.2.2 Growing adoption of PD-1 inhibitors for lung cancer treatment |
4.2.3 Advancements in immunotherapy research and development |
4.3 Market Restraints |
4.3.1 High cost associated with PD-1 inhibitors |
4.3.2 Stringent regulatory requirements for approval and reimbursement |
4.3.3 Competition from alternative treatment options like chemotherapy and targeted therapy |
5 Germany PD-1 Non-Small Cell Lung Cancer Market Trends |
6 Germany PD-1 Non-Small Cell Lung Cancer Market, By Types |
6.1 Germany PD-1 Non-Small Cell Lung Cancer Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Drug Type, 2021 - 2031F |
6.1.3 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-1 Inhibitors, 2021 - 2031F |
6.1.4 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-L1 Inhibitors, 2021 - 2031F |
6.1.5 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Combination Therapy, 2021 - 2031F |
6.1.6 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Monotherapy, 2021 - 2031F |
6.1.7 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Adjuvant Therapy, 2021 - 2031F |
6.2 Germany PD-1 Non-Small Cell Lung Cancer Market, By Therapy Type |
6.2.1 Overview and Analysis |
6.2.2 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.2.3 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.2.4 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Radiation Therapy, 2021 - 2031F |
6.2.5 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Surgery, 2021 - 2031F |
6.2.6 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Palliative Care, 2021 - 2031F |
6.3 Germany PD-1 Non-Small Cell Lung Cancer Market, By Treatment Stage |
6.3.1 Overview and Analysis |
6.3.2 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By First-Line Treatment, 2021 - 2031F |
6.3.3 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Second-Line Treatment, 2021 - 2031F |
6.3.4 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Advanced-Stage Treatment, 2021 - 2031F |
6.3.5 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Recurrent Cancer Treatment, 2021 - 2031F |
6.3.6 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Metastatic Cancer Treatment, 2021 - 2031F |
6.4 Germany PD-1 Non-Small Cell Lung Cancer Market, By Mode of Action |
6.4.1 Overview and Analysis |
6.4.2 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Targeted Therapy, 2021 - 2031F |
6.4.3 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Checkpoint Inhibitors, 2021 - 2031F |
6.4.4 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Biomarker-Based Therapy, 2021 - 2031F |
6.4.5 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immune Checkpoint Modulation, 2021 - 2031F |
6.4.6 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By T-Cell Activation, 2021 - 2031F |
6.5 Germany PD-1 Non-Small Cell Lung Cancer Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.5.3 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Research Labs, 2021 - 2031F |
6.5.4 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Oncology Centers, 2021 - 2031F |
6.5.5 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Clinics, 2021 - 2031F |
6.5.6 Germany PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Diagnostic Centers, 2021 - 2031F |
7 Germany PD-1 Non-Small Cell Lung Cancer Market Import-Export Trade Statistics |
7.1 Germany PD-1 Non-Small Cell Lung Cancer Market Export to Major Countries |
7.2 Germany PD-1 Non-Small Cell Lung Cancer Market Imports from Major Countries |
8 Germany PD-1 Non-Small Cell Lung Cancer Market Key Performance Indicators |
8.1 Patient survival rates post PD-1 inhibitor treatment |
8.2 Rate of adoption of PD-1 inhibitors in lung cancer treatment protocols |
8.3 Number of clinical trials evaluating PD-1 inhibitors for non-small cell lung cancer in Germany |
9 Germany PD-1 Non-Small Cell Lung Cancer Market - Opportunity Assessment |
9.1 Germany PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Germany PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Therapy Type, 2021 & 2031F |
9.3 Germany PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Treatment Stage, 2021 & 2031F |
9.4 Germany PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Mode of Action, 2021 & 2031F |
9.5 Germany PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Germany PD-1 Non-Small Cell Lung Cancer Market - Competitive Landscape |
10.1 Germany PD-1 Non-Small Cell Lung Cancer Market Revenue Share, By Companies, 2024 |
10.2 Germany PD-1 Non-Small Cell Lung Cancer Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here